Apply Now- Clinical and Basic Research Awards

Deadline- December 15

The purpose of the OARSI Clinical Research and Basic Science Awards is to recognize excellence in clinical and basic research related to osteoarthritis. The two award recipients are required to present a talk at the OARSI Congress in Las Vegas in April, 2017.  Clinical research domains include, but are not limited to,  epidemiology and health-services research, clinical outcomes, translational research, and therapeutics, encompassing all phases of research having clinical implications.   The basic research targets include all areas of basic science with relevance to osteoarthritis. Research for both awards must have been conducted within the last five years.

Congress Registration Now Open

Registration is now open for the 2017 World Congress on Osteoarthritis April 27-30 in Las Vegas.  New features this year include:

  • Inaugural Clinical Trials Course
  • Three Pre Congress workshops on Prevention, Pain and Imaging
  • Breakfast Poster Tours
  • Social Media Savvy Young Investigator Session  
  • and more.... 

 

OARSI Issues White Paper to the FDA

OARSI submitted a white paper asking the FDA to consider OA as a serious disease. OARSI is concerned about the growing population of OA patients, many of whom may experience progressive disability and decreased quality of life. The detailed paper outlines the evidence, demonstrating that OA fulfills the definition of seriousness used in the guidance regarding accelerated approvals by the FDA.

The white paper addresses:

  • The increasing prevalence of OA along with the risk factors that have been identified 
  • The associated morbidity and severity of the disease 
  • Newly developed evidence of an increased mortality risk in the US in OA patients

Learn More about OARSI

Spread the Word